Lixte Biotechnology Holdings Inc Stock News

-- Company Relocates Corporate Headquarters to Boca Raton -- Boca Raton, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced that Lourdes Felix and Guy Primus have joined the Compa...

LIXTE (NASDAQ: LIXT) publishes new data showing that its lead compound LB-100 can mediate activation of oncogenic signaling, which is toxic to cancer cells

LIXTE Biotechnology (Nasdaq: LIXT) advancing its clinical strategy by focusing on high-need, high-value cancer indications that currently offer limited tre

DENVER, Aug. 19, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, revisits the LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways, Nature Reviews Ca...

-Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two New Board Members- -Re-Establishes Scientific Advisory Committee- - Reports on New Findings Published in Scientific Journal Nature  that Validate LIXTE's Ongoing Clinical Trials with LB-100- -Launches New Pre-Clinical Study- PASADENA, Calif, Aug. 18, 2025...

Breakthrough Protein Phosphatase 2A inhibitor LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer 24/7 Market News Issues Corrected Information on Previously issued Press Release with same title DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market ne...

DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the epigenetic modulation of key cellular pathways. 2025 is shapin...

LIXTE's (Nasdaq:LIXT) BoD approved a bold new treasury policy to diversify its corporate reserves into cryptocurrency, including $BTC & potentially others